Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • apa.csl
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Different delivery of tumour to human dendritic cells to raise anti tumour T-lymphocyte response
2002 (English)Independent thesis Advanced level (degree of Master (One Year))Student thesis
Abstract [sv]

Konventionella behandlingar av cancer har många bieffekter och resulterar vanligtvis inte till permanent bot. Därför är det ett angeläget behov av nya cancerterapier. Immunoterapi är en ny lovande behandling som använder kroppens eget immunförsvar till att bekämpa tumörer. Immunoterapin har haft viss framgång men är långt ifrån komplett. Bland anledningarna till detta har varit den begränsade tillgången av tumörassocierade antigener och oförmågan att leverera sådana antigen på ett sätt som väcker immunförsvaret mot dem i patienter med cancer. Syftet med den här studien var att studera dendritiska cellers (DCs) roll i att väcka cytotoxiska T-lymphocyter mot prostata specifikt antigen (PSA) samt att jämföra tre olika sätt att leverera PSA till DCs. DCs är de mest potenta antigenpresenterande cellerna i kroppen. De tre levereringssätten var adenovirus, elektroporering av mRNA och pulsning av rekombinant protein. De behandlade DCs användes sedan till att stimulera T-lymphocyter till att känna igen PSA. T-lymphocyterna testades sedan mot PSA positiva prostatacancer cellinjer och IFN-g produktionen analyserades med ELISA (Enzymed Linked Immunosorbent Assay) och ELISPOT (Enzymed Linked Immunospot Assay). Resultaten visar att DCs som var elektroporerade med mRNA var bäst i att stimulera T-lymphocyter till att känna igen PSA.

Abstract [en]

Conventional treatments of cancer have many side effects and usually do not result in permanent cure. Therefore is there an urgent need for new cancer therapies. Immunotherapy is a new promising treatment which uses the body’s own immune system to fight tumours. Immunotherapeutic approaches have had some success but far from complete. Among the reasons for this have been the limited availability of tumour- associated antigens and the inability to deliver such antigens in manner that renders them immunogenic in patiens with cancer. The aim of this study was to study the role of dendritic cells (DCs) to raise Cytotoxic T-lymphocytes (CTLs) against prostate specific antigen (PSA) and to compare three different ways of delivering PSA to DCs. DCs are the most potent antigen-presenting cells in the body. The means of delivery were adenovirally mediated gene transfer, electroporation with mRNA and pulsing with recombinant protein. The loaded DCs were used to stimulate T-lymphocytes to recognize PSA. The T-lymphocytes were tested against PSA positive prostate carcinoma cell lines and IFN-_ production were analysed with ELISA (Enzymed Linked Immunosorbent Assay) and ELISPOT (Enzymed Linked Immunospot Assay). The results showed that DCs loaded with mRNA using electroporation were best in stimulating T-lymphocytes to recognize PSA.

Place, publisher, year, edition, pages
2002. , p. 42
Identifiers
URN: urn:nbn:se:kau:diva-52481Local ID: KEM-16OAI: oai:DiVA.org:kau-52481DiVA, id: diva2:1101007
Subject / course
Chemistry
Available from: 2017-05-29 Created: 2017-05-29

Open Access in DiVA

No full text in DiVA

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 163 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • apa.csl
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf